Teva unveils new data and expert insights on the emerging public health issue of multiple chronic conditions during the week of 70th World Health Assembly

Data presented during the week of 70th World Health Assembly, in Geneva, placed a spotlight on an emerging global public healthcare challenge – the growing burden of managing multiple chronic conditions. The data, presented to a group of renowned public healthcare experts, convened by the International Association of Patient Organizations (IAPO) and Teva, showed a worrying gap in understanding and planning of the management of patients diagnosed with multiple chronic conditions (polychronic).

Teva unveils new data and expert insights on the emerging public health issue of multiple chronic conditions during the week of 70th World Health Assembly

 

As the population ages, there is a rising tide of patients struggling with more than one disease. Treatment of these patients is more complex and costly, straining the healthcare system with potential adverse drug-drug interactions, falling treatment adherence, and higher hospital re-admittance rates .


Among the key insights:

  • The odds of incurring a preventable hospital admission due to an adverse event rise by 1200% in patients diagnosed with two conditions compared to none.
  • The odds of incurring a preventable hospital admission due to an adverse event rise by 500% in patients diagnosed with one condition compared to none.
  • Furthermore, depression is over three times more likely in people with certain chronic conditions and is associated with a three-fold lower treatment adherence rate .
  • Complex and poorly understood interactions also come into play in polychronic situations. For example, there has been little recognition of the relationship between diabetes and tuberculous (TB), whereby diabetes increases the risk of contracting TB, and yet the treatment of TB interferes with that of diabetes.
  • These types of challenges, if not properly addressed, can massively impact healthcare outcomes, patient lives and even country development.


“For the patient, this doesn’t mean just taking more medications, it means dealing with a variety of healthcare specialists who need to ensure they are providing well-coordinated care. That’s challenging for healthcare systems focused on targeting specific diseases.” Said Dr Cother Hajat Director, former Director of Global Health Strategy, The Vitality Group, one of the expert presenters at the meeting.

“There is a unique role that industry can play in helping to find solutions to this growing public health challenge. Teva is committed to playing its part. We can harness the world's largest medicine cabinet with digital and other technology platforms to find ways of directing targeted drug development and creating patient-support programs that could make tangible improvements to this issue,” commented Iris Beck-Codner, Group Executive Vice President, Corporate Marketing & Communications, Teva, and panel co-chair.

Meeting participants ranging from the NCD Alliance (Non-Communicable Diseases), IBM Watson, patient advocacy organizations and leading public health experts, warned that the health care system is ill-equipped to deal with the rising burden:

  • "Treating each individual disease in a silo is a historic notion," stated Ms. Katie Dane, Executive Director of the NCD Alliance.
  • "We need a multifaceted approach within an integrated healthcare system – and we need it quickly" said Kawaldip Sehmi, IAPO Chief Executive Officer.
  • Professor Peter Boyle, President, International Prevention Research Institute, Lyon, Franc , outlined the need, for a multifaceted and multi-stakeholder plan before “a crisis happens”.
  • "Technology can play a vital role in both building deeper understanding and in day-to-day management of the increasing number of patients coping with multiple chronic conditions" said Dr Byron Scott, Deputy Chief Health Officer, IBM Watson Health. "Wearables, machine learning and AI will be vital in spotting connections and implications that are not normally obvious. These technologies will be critical in meeting the challenges posed by the complexity of aging populations and increasing chronic conditions."
  • "We must have a team-based approach to healthcare" said Penney Cowan, one of the panelists at the event and IAPO Board Member and Founder& Executive Director of the American Chronic Pain Association (ACPA). "The patient is part of that team, playing an active partnership role in the treatment chain”.
  • “There is really need for societal change, at this point in time young people are sleep walking into these chronic, avoidable diseases.” Said Dr. Mary Baker, Immediate Past preseidenr, European Brain Council


The experts have pledged to identify key targets to help tackle this growing issue. Such targets will be aligned with the United Nations’ Sustainable Development Goal to ‘ensure health and well-being for all, at every stage of life’, and discussed at a follow-on meeting scheduled to take place later this year.

Cancer, heart disease, obesity, aging, dementia, depression… It's not just one illness we need to focus on, but all of them together – Teva is committed to seek solutions for patients with multiple chronic conditions (polychronic)

Through our expertise and influence, Teva is uniquely suited to lead a global effort to address polychronic diseases. Together, we will develop solutions that deliver lasting economic, societal and social impact to fulfil Teva's promise of creating better days for patients across the globe.